Cargando…
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent progn...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099860/ https://www.ncbi.nlm.nih.gov/pubmed/33953185 http://dx.doi.org/10.1038/s41523-021-00256-2 |
_version_ | 1783688662317268992 |
---|---|
author | Goncalves, Anthony Finetti, Pascal Birnbaum, Daniel Bertucci, François |
author_facet | Goncalves, Anthony Finetti, Pascal Birnbaum, Daniel Bertucci, François |
author_sort | Goncalves, Anthony |
collection | PubMed |
description | CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent prognostic value in the Luminal B subtype and not in the other subtypes. In Luminal B patients receiving adjuvant endocrine therapy but no chemotherapy, CINSARC identified patients with different 5-year DFS (90% [95%CI 86–95] in low-risk vs. 79% [95%CI 75–84] in high-risk, p = 1.04E−02). Luminal B CINSARC high-risk tumors were predicted to be less sensitive to endocrine therapy and CDK4/6 inhibitors, but more vulnerable to homologous recombination targeting and immunotherapy. We concluded that CINSARC adds prognostic information to that of clinicopathological features in Luminal B breast cancers, which might improve patients’ stratification and better orient adjuvant treatment. Moreover, it identifies potential therapeutic avenues in this aggressive molecular subtype. |
format | Online Article Text |
id | pubmed-8099860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80998602021-05-10 The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer Goncalves, Anthony Finetti, Pascal Birnbaum, Daniel Bertucci, François NPJ Breast Cancer Article CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent prognostic value in the Luminal B subtype and not in the other subtypes. In Luminal B patients receiving adjuvant endocrine therapy but no chemotherapy, CINSARC identified patients with different 5-year DFS (90% [95%CI 86–95] in low-risk vs. 79% [95%CI 75–84] in high-risk, p = 1.04E−02). Luminal B CINSARC high-risk tumors were predicted to be less sensitive to endocrine therapy and CDK4/6 inhibitors, but more vulnerable to homologous recombination targeting and immunotherapy. We concluded that CINSARC adds prognostic information to that of clinicopathological features in Luminal B breast cancers, which might improve patients’ stratification and better orient adjuvant treatment. Moreover, it identifies potential therapeutic avenues in this aggressive molecular subtype. Nature Publishing Group UK 2021-05-05 /pmc/articles/PMC8099860/ /pubmed/33953185 http://dx.doi.org/10.1038/s41523-021-00256-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Goncalves, Anthony Finetti, Pascal Birnbaum, Daniel Bertucci, François The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer |
title | The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer |
title_full | The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer |
title_fullStr | The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer |
title_full_unstemmed | The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer |
title_short | The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer |
title_sort | cinsarc signature predicts the clinical outcome in patients with luminal b breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099860/ https://www.ncbi.nlm.nih.gov/pubmed/33953185 http://dx.doi.org/10.1038/s41523-021-00256-2 |
work_keys_str_mv | AT goncalvesanthony thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT finettipascal thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT birnbaumdaniel thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT bertuccifrancois thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT goncalvesanthony cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT finettipascal cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT birnbaumdaniel cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT bertuccifrancois cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer |